Latest News
Mylan unveils US FDA approved XULANE (Norelgestromin/Ethinyl Estradiol Transdermal System 150/35 mcg per day) for the prevention of pregnancy
17 April 2014 - Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the market launch of its US Food and Drug Administration (FDA) approved XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).

This launch has been initiated by the company's US based subsidiary, Mylan Pharmaceuticals.

The company added XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day) is the generic version of Janssen Pharmaceuticals' ORTHO EVRA (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).

XULANE is reportedly indicated for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception.

For the 12 months ending 30 December 2013, ORTHO EVRA had US sales of approximately USD152.9m, according to IMS Health.

Login
Username:

Password: